Neoadjuvant Chemotherapy for Ovarian Cancer

For High-Definition, Click

Current practice for the treatment of ovarian cancer involves primary de-bulking surgery followed by chemotherapy. Neoadjuvant chemotherapy, or the delivery of chemotherapy before surgery, tends to be used in patients who are not candidates for upfront de-bulking surgery, observes James Tate Thigpen, MD, and Robert A. Burger, MD.

Warner K. Huh, MD, notes that reliable preoperative markers that predict which individuals will have successful de-bulking are not available, and candidates for surgery are still largely based on comorbidities and performance status. If patients meet a certain threshold, they may be better served with neoadjuvant chemotherapy.

In clinical trials, the ability to de-bulk to no gross residual was greater in the neoadjuvant chemotherapy group. However, this cohort did not show a survival advantage. Moreover, de-bulking rates for primary de-bulking surgery ranged from 30% to 83%. Thigpen comments that the variable frequency in which patients achieve optimal de-bulking and the unclear data surrounding neoadjvaunt chemotherapy leaves him not yet comfortable simply choosing one approach over another.

Related Videos
Thomas Marron, MD, PhD
Kimberly Cannavale, MPH
Jean-Marc Classe, MD, PhD, Nantes Université
Suresh Ramalingam, MD, and Chandler Park, MD
Amin Nassar, MD
Emil Lou, MD, PhD, FACP
Bradley R. Corr, MD, associate professor, LeBert Suess Family Endowed Professor in Ovarian Cancer Research, gynecologic oncology team, the University of Colorado Anschutz Medical Campus
Hye Sook Chon, MD, gynecologic oncologist, Gynecologic Oncology Program, Moffitt Cancer Center